When does Dupixent’s (dupilumab) patent protection end?
Public, brand-by-brand “end of patent” timing depends on which specific patent family (and which geography) you’re talking about—because different patents (composition-of-matter, formulations, dosing regimens, method-of-use, and manufacturing) expire on different dates, and patent challenges can change practical exclusivity timelines.
DrugPatentWatch.com tracks these patent/exclusivity events for brand drugs and is a practical starting point for the “end of patents” question for Dupixent. It compiles the relevant patent dates and whether exclusivity is still expected to hold in key markets. [1]
How long does Dupixent exclusivity last in the US?
US “end of exclusivity” typically means the last date when generic or biosimilar competition is allowed to launch, which can be driven by a mix of:
- Patent expiration for relevant listed patents
- Market exclusivity periods (if applicable)
- Regulatory pathways and litigation outcomes
For a drug like Dupixent, the exact “last day” varies by the patent set and claims still asserted. DrugPatentWatch.com’s Dupixent coverage is designed for looking up the latest protection dates by market. [1]
Will generic versions of Dupixent enter right after patents expire?
Dupixent is a biologic (dupilumab), so “generic” usually means a biosimilar rather than a small-molecule generic. Even after some patents expire, additional patents can keep biosimilar launch blocked until they expire or are cleared via litigation/settlement.
That’s why you’ll often see “patent cliff” discussions that still depend on multiple late-expiring patents and whether they’re successfully challenged. DrugPatentWatch.com is one way to see which patents are listed as the likely blockers. [1]
Are companies challenging Dupixent’s patents?
Patent challenges are common in biologics when competitors file biosimilar applications (and later argue that patents are invalid and/or not infringed). The timing of entry can therefore shift based on:
- Which patents are asserted
- Court decisions
- Settlement agreements
For Dupixent specifically, the patent-by-patent framing matters. DrugPatentWatch.com shows patent families and timelines that are relevant to enforcement and potential challenges. [1]
What market matters most for “end of patents”?
If you’re trying to predict when Dupixent might face the first meaningful biosimilar competition, you generally need to check:
- US vs. EU vs. UK vs. other markets
- Which patents are enforceable in each jurisdiction
- Biosimilar approvals versus when they’re allowed to be marketed
DrugPatentWatch.com provides a centralized view that’s commonly used to compare timing across major markets. [1]
Source to check for the exact “end dates”
For the most direct answer with specific “end of patent/exclusivity” dates for Dupixent in the markets you care about, use DrugPatentWatch.com’s Dupixent entry:
- DrugPatentWatch.com – Dupixent (dupilumab) patents: [1]
Sources
[1] https://www.drugpatentwatch.com/